Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose, 5% in Water Clear all
Completed Phase 1 Interventional

Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury

NCT00930202
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Conivaptan (Vaprisol)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

NCT04649541
View directory record Official record
Conditions
Safety
Interventions
MRX-8, Placebo
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 6, 2026, 7:10 PM EDT
Enrolling by invitation No phase listed Observational

International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia

NCT07576036
View directory record Official record
Conditions
Hyponatremia Symptomatic, Osmotic Demyelination Syndrome, Cerebral Edema
Interventions
Hypertonic 3% saline
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 6, 2026, 7:10 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Obstructive Sleep Apnea and Glucose Metabolism

NCT03408613
View directory record Official record
Conditions
Sleep Apnea, Glucose Metabolism Disorders
Interventions
Positive Airway Pressure, Supplemental Oxygen, Sham
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
30 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

NCT01092325
View directory record Official record
Conditions
Heart Failure
Interventions
CXL-1020, Placebo for CXL-1020 Cohort 1, Placebo for CXL-1020 Cohort 2, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 3 Interventional

Ulimorelin Study of Efficacy and Safety (ULISES 008)

NCT01296620
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Ulimorelin Intravenously (IV), Ulimorelin Invtravenously (IV), 5% dextrose in water
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Glendale, California • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

NCT00450801
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Methotrexate, Thalidomide, Vincristine, Mesna, Filgrastim (G-CSF), Granisetron, Decadron
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-042 Healthy Volunteer Dose Escalation Study

NCT01638104
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ANX-042, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT00878254
View directory record Official record
Conditions
Mantle-Cell Lymphoma
Interventions
G-CSF, Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Mesna, Methotrexate, Vincristine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

NCT00004203
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
oxaliplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 6, 2026, 7:10 PM EDT
Withdrawn Phase 2 Interventional

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276
View directory record Official record
Conditions
Influenza
Interventions
CR8020, CR6261, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

NCT04294472
View directory record Official record
Conditions
BK Virus Infection
Interventions
MAU868, Placebo
Drug · Other
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

NCT04935359
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

NCT00393029
View directory record Official record
Conditions
Anti-p53 TCR-Gene
Interventions
anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 6, 2026, 7:10 PM EDT
Recruiting Not applicable Interventional

Exploring Water-free Sodium Storage

NCT06872645
View directory record Official record
Conditions
Peritoneal Dialysis, Heart Failure
Interventions
5% Dextrose/Water, 1.5% standard PD fluid
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

EASI Access II --- Follow-up Study to the EASI Access Trial

NCT00740727
View directory record Official record
Conditions
Disaster Medicine, Difficult Intravenous Access, Dehydration
Interventions
Human recombinant hyaluronidase (HRH), Enzymatically Augmented Subcutaneous Infusion (EASI) line placement
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

NCT05574400
View directory record Official record
Conditions
Postoperative Delirium, Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Interventions
Dextrose Water, Caffeine citrate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 6, 2026, 7:10 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT02111863
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Food Preservative on Glucose Homeostasis

NCT01179945
View directory record Official record
Conditions
Overweight
Interventions
benzoate containing test drinks, non sodium benzoate containing test drinks
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 6, 2026, 7:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

NCT01583686
View directory record Official record
Conditions
Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer
Interventions
Fludarabine, Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL), Cyclophosphamide, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 6, 2026, 7:10 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

NCT03824808
View directory record Official record
Conditions
Kidney Cancer, Prostate Cancer
Interventions
Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of TRV130 for the Treatment of Pain After Bunionectomy

NCT02100748
View directory record Official record
Conditions
Acute Pain
Interventions
TRV130, Morphine, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 6, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Results available

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

NCT03000283
View directory record Official record
Conditions
Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Stroke
Interventions
Conivaptan
Drug
Lead sponsor
Jesse Corry
Other
Eligibility
19 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 6, 2026, 7:10 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 6, 2026, 7:10 PM EDT